enGene Therapeutics Inc. SEC filings ENGN

enGene Therapeutics Inc. has 267 filings in SEC EDGAR's recent list, going back to Jun 14, 2023. Its latest annual report, Form ARS, was filed on May 8, 2026 for the period ended Oct 31, 2025. The latest quarterly report (Form 10-Q) was filed on Sep 8, 2026, covering the quarter ended Jul 31, 2026. The most recent current report (Form 8-K) was filed on Sep 8, 2026 (results of operations). The company's fiscal year ends on October 31.

Form Description Filed Period
10-Q Quarterly report Sep 8, 2026 Jul 31, 2026
10-Q Quarterly report Jun 15, 2026 Apr 30, 2026
10-Q Quarterly report Mar 9, 2026 Jan 31, 2026
10-Q Quarterly report Sep 11, 2025 Jul 31, 2025
10-Q Quarterly report Jun 12, 2025 Apr 30, 2025
10-Q Quarterly report Mar 10, 2025 Jan 31, 2025
10-Q Quarterly report Sep 10, 2024 Jul 31, 2024
10-Q Quarterly report Jun 14, 2024 Apr 30, 2024
10-Q Quarterly report Mar 11, 2024 Jan 31, 2024

Showing 9 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
ENGN (Nasdaq), ENGNW (Nasdaq)
Fiscal year ends
October 31
Incorporated in
Canada (Federal Level)
Headquarters
Saint-Laurent
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1980845
Former names
enGene Holdings Inc. (until Mar 9, 2026)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.